MYL(600993) 财富在线· Cai Fu Zai Xian·2025-04-09 06:18Core Insights - The company, Mayinglong Pharmaceutical Group Co., Ltd., reported a record high net profit of 528 million yuan for 2024, marking a year-on-year growth of 19.14% [1] - The company attributes its performance to a combination of digital intelligence, green practices, and innovation, which it refers to as "new quality productivity" [5] Digital Transformation - Mayinglong is implementing digital innovations across its entire supply chain, achieving 100% digital management of core production lines and utilizing digital twin technology for real-time production monitoring [2] - The company has introduced automated guided vehicles (AGVs) for product transport, enhancing logistics efficiency while reducing energy consumption [2] - The establishment of a comprehensive digital marketing system has improved consumer engagement through various channels, including short videos and live streaming [2] Green Practices - The company integrates ESG principles into its operations, actively pursuing energy-saving and carbon-reduction initiatives in response to national dual carbon policies [3] - Investments in advanced green production lines and environmental management systems have led to significant reductions in energy consumption and emissions [3] - Mayinglong has been recognized as a "National Green Factory" and a green manufacturing demonstration enterprise in Hubei province [3] AI and Innovation - Mayinglong has developed an intelligent manufacturing cloud platform that connects data from suppliers and customers, enhancing coordination across production, supply, and sales [4] - The company focuses on strategic areas such as proctology, ophthalmology, and dermatology, with significant advancements in product development, including several new drug registrations [4] - In 2024, the company invested 66.69 million yuan in R&D, successfully completing the development of 60 health products across various sectors [4]